what not to take with semaglutide Who Should GLP-1 Drugs? Semaglutide for Weight Loss: How

While both target metabolic disease, tirzepatide is a GIP/GLP1 dual agonist injectable, whereas orforglipron is a selective, oral GLP1 receptor agonist

However, independent long-term self-administration without medical oversight is not recommended

The NIHs Office of Dietary Supplements says most peoples results fall somewhere between about 200 and 800 picograms per milliliter

[1] Understanding how these medications work throughout the body helps contextualise potential side effects, including changes in sweating patterns that some patients report

Dosing is typically increased gradually over 1620 weeks to reduce side effects like nausea